Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling (Q46847848)

25 December 2017

title

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling (English)

1 reference

25 December 2017

author name string

Mangili G

1

1 reference

25 December 2017

Petrone M

2

1 reference

25 December 2017

Gentile C

3

1 reference

25 December 2017

De Marzi P

4

1 reference

25 December 2017

Viganò R

5

1 reference

25 December 2017

Rabaiotti E

6

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

25 December 2017

published in

Gynecologic Oncology

1 reference

25 December 2017

volume

108

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

332-335

1 reference

25 December 2017

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.021

10.1016/J.YGYNO.2007.10.021

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017